Eli Lilly and Co. on March 14 said the company’s experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32 percent compared with a placebo in a mid-stage trial of patients at an early stage of the mind wasting disease.

A small trial of Eli Lilly’s donanemab showed the experimental Alzheimer’s drug slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease.

Some 21 percent of patients with advanced brain cancer treated with a modified polio vaccine were alive after three years, compared with 4 percent with similar tumors who received standard therapies.

Nearly 20 percent of American adolescents, or one in five, has suffered a concussion, according to newly released statistics.

Juno Therapeutics Inc. said two more patients had died after suffering brain swelling during a trial of its experimental genetically engineered leukemia drug.